Oncobiologics Inc (NASDAQ:ONS) has been assigned an average broker rating score of 3.00 (Hold) from the one analysts that cover the company, Zacks Investment Research reports. One research analyst has rated the stock with a hold recommendation. Oncobiologics’ rating score has declined by 200% in the last three months as a result of various analysts’ ratings changes.
Analysts have set a 1 year consensus target price of $11.00 for the company, according to Zacks. Zacks has also assigned Oncobiologics an industry rank of 190 out of 265 based on the ratings given to related companies.
Several brokerages have recently weighed in on ONS. Barclays cut shares of Oncobiologics from an “overweight” rating to an “equal weight” rating in a research note on Monday, January 29th. ValuEngine upgraded shares of Oncobiologics from a “strong sell” rating to a “sell” rating in a research note on Friday.
In related news, CFO Lawrence A. Kenyon sold 26,165 shares of the stock in a transaction that occurred on Friday, December 22nd. The shares were sold at an average price of $1.13, for a total value of $29,566.45. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Pankaj Mohan sold 114,677 shares of the stock in a transaction that occurred on Thursday, January 4th. The stock was sold at an average price of $1.17, for a total transaction of $134,172.09. The disclosure for this sale can be found here. Insiders sold a total of 284,508 shares of company stock valued at $328,317 over the last three months. 33.50% of the stock is currently owned by insiders.
An institutional investor recently raised its position in Oncobiologics stock. Sabby Management LLC raised its stake in shares of Oncobiologics Inc (NASDAQ:ONS) by 5.7% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,365,763 shares of the company’s stock after buying an additional 127,293 shares during the quarter. Sabby Management LLC owned about 9.59% of Oncobiologics worth $2,371,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 17.90% of the stock is currently owned by institutional investors and hedge funds.
Oncobiologics (NASDAQ ONS) opened at $1.14 on Friday. Oncobiologics has a one year low of $0.78 and a one year high of $3.77. The company has a current ratio of 0.14, a quick ratio of 0.14 and a debt-to-equity ratio of -0.40.
TRADEMARK VIOLATION NOTICE: This piece of content was published by Stock Observer and is owned by of Stock Observer. If you are viewing this piece of content on another site, it was stolen and republished in violation of U.S. and international copyright legislation. The legal version of this piece of content can be viewed at https://www.thestockobserver.com/2018/02/05/zacks-oncobiologics-inc-ons-given-consensus-rating-of-hold-by-analysts.html.
Oncobiologics Company Profile
Oncobiologics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing, manufacturing and commercializing biosimilar therapeutics. It is focused on monoclonal antibodies (mAbs) in the disease areas of immunology and oncology. The Company offers BioSymphony Platform.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Oncobiologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncobiologics and related companies with MarketBeat.com's FREE daily email newsletter.